

Lactovac Suspension for injection

Not
authorised

- Bovine rotavirus A, strain 1005/78, Inactivated
- Bovine rotavirus A, strain Holland, Inactivated
- Bovine coronavirus, strain 800, Inactivated
- Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain S1091/83, Inactivated

Product identification

Medicine name:

Lactovac Suspension for injection

Active substance:

Bovine rotavirus A, strain 1005/78, Inactivated

Bovine rotavirus A, strain Holland, Inactivated

Bovine coronavirus, strain 800, Inactivated

Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain S1091/83, Inactivated

Target species:

Cattle

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Bovine rotavirus A, strain 1005/78, Inactivated

1.00 relative potency / 1.00 Dose

Bovine rotavirus A, strain Holland, Inactivated

1.00 relative potency / 1.00 Dose

Bovine coronavirus, strain 800, Inactivated

1.00 relative potency / 1.00 Dose

Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain S1091/83, Inactivated

1.00 relative potency / 1.00 Dose

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

-

Cattle

- Meat and offal. 0 day

- Milk. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AL01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Surrendered

Authorised in:

Estonia

Package description:

Type I glass vial containing 5 ml. The glass vial is closed with a type I rubber stopper, sealed with an aluminium crimp cap. Cardboard box with 10 glass vials of 1 dose (5 ml).

Type I glass vial containing 25 ml. The glass vial is closed with a type I rubber stopper, sealed with an aluminium crimp cap. Cardboard box with 1 glass vial of 5 doses (25 ml).

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Belgium

Marketing authorisation date:

30/08/2020

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

State Agency Of Medicines

Authorisation number:

2248

Date of authorisation status change:

21/06/2022

Reference member state:

Ireland

Procedure number:

IE/V/0417/001/E/002

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.